IL263568A - A process for producing a DNA vaccine for cancer immunotherapy - Google Patents

A process for producing a DNA vaccine for cancer immunotherapy

Info

Publication number
IL263568A
IL263568A IL263568A IL26356818A IL263568A IL 263568 A IL263568 A IL 263568A IL 263568 A IL263568 A IL 263568A IL 26356818 A IL26356818 A IL 26356818A IL 263568 A IL263568 A IL 263568A
Authority
IL
Israel
Prior art keywords
production
dna vaccine
cancer immunotherapy
immunotherapy
cancer
Prior art date
Application number
IL263568A
Other languages
English (en)
Hebrew (he)
Inventor
Lubenau Heinz
Original Assignee
Vaximm Ag
Lubenau Heinz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Ag, Lubenau Heinz filed Critical Vaximm Ag
Publication of IL263568A publication Critical patent/IL263568A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001109Vascular endothelial growth factor receptors [VEGFR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001166Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168Mesothelin [MSLN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00118Cancer antigens from embryonic or fetal origin
    • A61K39/001182Carcinoembryonic antigen [CEA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL263568A 2016-07-13 2018-12-06 A process for producing a DNA vaccine for cancer immunotherapy IL263568A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16001550 2016-07-13
PCT/EP2017/067590 WO2018011289A1 (en) 2016-07-13 2017-07-12 Process for the production of a dna vaccine for cancer immunotherapy

Publications (1)

Publication Number Publication Date
IL263568A true IL263568A (en) 2019-01-31

Family

ID=56418345

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263568A IL263568A (en) 2016-07-13 2018-12-06 A process for producing a DNA vaccine for cancer immunotherapy

Country Status (13)

Country Link
US (2) US10821163B2 (OSRAM)
EP (1) EP3484503A1 (OSRAM)
JP (2) JP7098599B2 (OSRAM)
KR (2) KR20230079514A (OSRAM)
CN (1) CN109475614A (OSRAM)
AU (1) AU2017295004B2 (OSRAM)
BR (1) BR112019000657A2 (OSRAM)
CA (1) CA3028549A1 (OSRAM)
IL (1) IL263568A (OSRAM)
MX (1) MX2019000415A (OSRAM)
RU (1) RU2019100079A (OSRAM)
SG (1) SG11201811258UA (OSRAM)
WO (1) WO2018011289A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018149982A1 (en) * 2017-02-17 2018-08-23 Vaximm Ag Novel vegfr-2 targeting immunotherapy approach
US11168326B2 (en) 2017-07-11 2021-11-09 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
NZ771198A (en) 2018-07-11 2024-11-29 Actym Therapeutics Inc Engineered immunostimulatory bacterial strains and uses thereof
EP3846844A1 (en) * 2018-09-05 2021-07-14 Vaximm AG Neoantigen targeting dna vaccine for combination therapy
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US20230121528A1 (en) 2020-01-13 2023-04-20 Vaximm Ag Salmonella-based dna vaccines in combination with an antibiotic
US20250340919A1 (en) * 2022-06-30 2025-11-06 Shimadzu Corporation Method for Preparing Analysis of Microorganisms, and Method for Analyzing Microorganisms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3892295T (lt) * 2011-05-24 2023-07-10 BioNTech SE Individualizuotos vakcinos nuo vėžio
LT2794849T (lt) * 2011-12-22 2017-12-11 Vaximm Ag Didelio produktyvumo susilpnintų salmonella padermių gamybos būdas
PL2869836T3 (pl) * 2012-07-05 2020-03-31 Vaximm Ag Szczepionka DNA do zastosowania u pacjentów z rakiem trzustki
WO2014173542A1 (en) * 2013-04-25 2014-10-30 Vaximm Ag Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1
KR20160130979A (ko) * 2013-12-18 2016-11-15 백심 게엠베하 암 면역요법을 위한 신규한 msln 표적화 dna 백신
EP3082853A2 (en) * 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine

Also Published As

Publication number Publication date
RU2019100079A (ru) 2020-08-13
JP2019521154A (ja) 2019-07-25
US11590215B2 (en) 2023-02-28
EP3484503A1 (en) 2019-05-22
JP2022097591A (ja) 2022-06-30
JP7098599B2 (ja) 2022-07-11
WO2018011289A1 (en) 2018-01-18
BR112019000657A2 (pt) 2019-04-24
AU2017295004B2 (en) 2020-08-13
KR20190027834A (ko) 2019-03-15
KR20230079514A (ko) 2023-06-07
US10821163B2 (en) 2020-11-03
US20220072112A1 (en) 2022-03-10
SG11201811258UA (en) 2019-01-30
CA3028549A1 (en) 2018-01-18
CN109475614A (zh) 2019-03-15
US20190183996A1 (en) 2019-06-20
MX2019000415A (es) 2019-03-28
AU2017295004A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
SG11201700367YA (en) Process for the production of cementitious material
IL263568A (en) A process for producing a DNA vaccine for cancer immunotherapy
GB2558335B (en) Novel processes for the production of oligonucleotides
IL252843A0 (en) A process for preparing a diarylthiohydantoin compound
SG11201706593SA (en) Methods for producing virus for vaccine production
PL3201252T3 (pl) Sposób wytwarzania poliestrów
SG11201704014WA (en) Process for preparing a polyetheramine
IL267508B (en) A process for the preparation of 2-pyridylethyl carboxamide derivatives
SG11201701502VA (en) A process for the production of adenovirus
ZA201604838B (en) Process for the production of synthesis gas
ZA201902125B (en) Process for the production of 2-alkylalkanol
SI3630738T1 (sl) Postopek za ustvarjanje ozanimoda
HUP1400114A2 (en) Method for the production of peptides
PL3295941T3 (pl) Sposób wytwarzania postaci a grapiprantu
HUE055687T2 (hu) Eljárás D-arginil-2,6-dimetil-L-tirozil-L-lizil-L-fenilalaninamid elõállítására
EP3114103A4 (en) Energy efficient batch recycle method for the production of biomolecules
PL3182981T3 (pl) Sposób wytwarzania izomaltooligosacharydów
PT3362405T (pt) Processo e unidade de produção para a produção de metanol
IL243795A0 (en) A process for the preparation of a quinazoline derivative
SG11201704523WA (en) A process for the manufacture of idalopirdine
GB201419234D0 (en) Hydrocarbon production process
IL255977B (en) A new process for the preparation of enzalutamide
GB201607540D0 (en) Hydrcarbon production process
EP3174878A4 (en) A process for the preparation of palbociclib
ZA201707922B (en) Multi-step process for no production